Treat Cancer without Chemotherapy? There Is Already a Medicine to Be Sold
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
The Japanese company Oncolys BioPharma began marketing in Japan its medicine Telomelysin, the first virotherapy treatment against esophageal cancer, which uses modified viruses in a laboratory. "The product is approved for use in patients with esophageal cancer who are not candidates for curative surgery or chemoradiotherapy, [...] The entry Japan markets the first virotherapy drug against esophageal cancer was first published in Informative Foc…
Telomelysin, which uses a virus to attack and infect cancer cells, has been in production since 2004 and will have a price of about 50,000 euros per patient.
The first treatment of virotherapy, which uses a modified virus in the laboratory, against esophageal cancer began today to be marketed in Japan and constitutes an option for radiation therapy or chemotherapy, more aggressive solutions.
Tokyo. Japanese company Oncolys BioPharma began marketing in Japan its medicine Telomelysin, the first virotherapy treatment against esophageal cancer, which uses modified viruses in a laboratory. "The product is approved for use in patients with esophageal cancer who are not candidates for curative surgery or chemoradiotherapy, offering a new treatment option alongside conventional therapies," the company said in a statement announcing the star…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
